Comparison of levosimendan and nitroglycerine in patients undergoing coronary artery bypass graft surgery

Annals of Cardiac Anaesthesia

Volumn 19, Issue 1, 2016, Pages 52-58

  Sahu, Manoj K ^a   Das, Anupam ^a   Malik, Vishwas ^a   Subramanian, Arun ^a   Singh, Sarvesh Pal ^a   Hote, Milind ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Coronary artery bypass; Levosimendan; Nitroglycerine; Pro brain natriuretic peptide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GLYCERYL TRINITRATE; LEVOSIMENDAN; BRAIN NATRIURETIC PEPTIDE; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PYRIDAZINE DERIVATIVE; SIMENDAN; VASODILATOR AGENT;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DRUG COST; EXTUBATION; FEMALE; HEART INDEX; HEART RATE; HUMAN; INTENSIVE CARE; LENGTH OF STAY; LOADING DRUG DOSE; MALE; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC VASCULAR RESISTANCE; AGED; BLOOD; COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECTS; HEART OUTPUT; HEMODYNAMICS; MIDDLE AGED; PROCEDURES;

AGED; CARDIAC OUTPUT; CARDIOTONIC AGENTS; CORONARY ARTERY BYPASS; CRITICAL CARE; FEMALE; HEMODYNAMICS; HUMANS; HYDRAZONES; LENGTH OF STAY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NITROGLYCERIN; PEPTIDE FRAGMENTS; PYRIDAZINES; RESPIRATION, ARTIFICIAL; VASODILATOR AGENTS;

EID: 84954558957     PISSN: 09719784     EISSN: 09745181     Source Type: Journal    
DOI: 10.4103/0971-9784.173020     Document Type: Article

References (30)

1. Christakis GT, Fremes SE, Naylor CD, Chen E, Rao V, Goldman BS. Impact of preoperative risk and perioperative morbidity on ICU stay following coronary bypass surgery. Cardiovasc Surg 1996;4: 29-35.
2. Loop FD, Higgins TL, Panda R, Pearce G, Estafanous FG. Myocardial protection during cardiac operations. Decreased morbidity and lower cost with blood cardioplegia and coronary sinus perfusion. J Thorac Cardiovasc Surg 1992;104: 608-18.
3. Levin R, Degrange M, Del Mazo C, Tanus E, Porcile R. Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol 2012;17: 125-30.
4. Tritapepe L, De Santis V, Vitale D, Guarracino F, Pellegrini F, Pietropaoli P, et al. Levosimendan pre-Treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth 2009;102: 198-204.
5. De Hert SG, Lorsomradee S, Cromheecke S, van Der Linden PJ. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg 2007;104: 766-73.
6. Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 2006;104: 556-69.
7. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 2005;111: 1504-9.
8. Pollesello P, Papp Z. The cardioprotective effects of levosimendan: Preclinical and clinical evidence. J Cardiovasc Pharmacol 2007;50: 257-63.
9. Lavine SJ, Campbell CA, Held AC, Johnson V. Effect of nitroglycerin-induced reduction of left ventricular filling pressure on diastolic filling in acute dilated heart failure. J Am Coll Cardiol 1989;14: 233-4.
10. Sage PR, de la Lande IS, Stafford I, Bennett CL, Phillipov G, Stubberfield J, et al. Nitroglycerin tolerance in human vessels: Evidence for impaired nitroglycerin bioconversion. Circulation 2000;102: 2810-5.
11. Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner SF. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest 1975;56: 978-85.
12. Breisblatt WM, Stein KL, Wolfe CJ, Follansbee WP, Capozzi J, Armitage JM, et al. Acute myocardial dysfunction and recovery: A common occurrence after coronary bypass surgery. J Am Coll Cardiol 1990;15: 1261-9.
13. Ukkonen H, Saraste M, Akkila J, Knuuti MJ, Lehikoinen P, Någren K, et al. Myocardial efficiency during calcium sensitization with levosimendan: A noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther 1997;61: 596-607.
14. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H, et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 2000;68: 522-31.
15. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Ca++ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 1997;333: 249-59.
16. Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther 1999;288: 316-25.
17. Gruhn N, Nielsen-Kudsk JE, Theilgaard S, Bang L, Olesen SP, Aldershvile J. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol 1998;31: 741-9.
18. Garlid KD, Dos Santos P, Xie ZJ, Costa AD, Paucek P. Mitochondrial potassium transport: The role of the mitochondrial ATP-sensitive K(+) channel in cardiac function and cardioprotection. Biochim Biophys Acta 2003;1606: 1-21.
19. Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K (ATP) channels. Anesth Analg 2000;90: 5-11.
20. Tritapepe L, De Santis V, Vitale D, Santulli M, Morelli A, Nofroni I, et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - A pilot study. Br J Anaesth 2006;96: 694-700.
21. Auchampach JA, Maruyama M, Cavero I, Gross GJ. Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning. Circulation 1992;86: 311-9.
22. De Santis V, Vitale D, Tritapepe L, Greco C, Pietropaoli P. Use of levosimendan for cardiogenic shock in a patient with the apical ballooning syndrome. Ann Intern Med 2008;149: 365-7.
23. Russ MA, Prondzinsky R, Christoph A, Schlitt A, Buerke U, Söffker G, et al. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med 2007;35: 2732-9.
24. McLean AS, Huang SJ, Nalos M, Ting I. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-Type natriuretic peptide. J Cardiovasc Pharmacol 2005;46: 830-5.
25. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikäinen PJ. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 2002;42: 43-51.
26. Masoumi G, Pour EH, Sadeghpour A, Ziayeefard M, Alavi M, Anbardan SJ, et al. Effect of different dosages of nitroglycerin infusion on arterial blood gas tensions in patients undergoing on- pump coronary artery bypass graft surgery. J Res Med Sci 2012;17: 123-7.
27. Masoumi G, Hidarpour E, Tabae AS, Ziayeefard M, Azarasa A, Abneshahidi A, et al. Evaluating hemodynamic outcomes of different dosages of intravenous nitroglycerin after coronary artery bypass graft surgery. J Res Med Sci 2011;16: 910-5.
28. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002;23: 1809-40.
29. Faida O, Said A, Samir P, Car D, Oteh M, Latif MA, et al. Nt-proBNP levels, as predictor of left ventricular systolic and diastolic dysfunction in patients with chronic heart failure. Int J Collab Res Intern Med Public Health 2012;4: 910-23.
30. Hammerer-Lercher A, Puschendorf B, Mair J. Cardiac natriuretic peptides: New laboratory parameters in heart failure patients. Clin Lab 2001;47: 265-77.